Učitavanje...
Nanoways to Overcome Docetaxel Resistance in Prostate Cancer
Prostate cancer is the most common non-cutaneous malignancy in American men. Docetaxel is a useful chemotherapeutic agent for prostate cancer that has been available for over a decade, but the length of the treatment and systemic side effects hamper compliance. Additionally, docetaxel resistance inv...
Spremljeno u:
| Glavni autori: | , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2014
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4100480/ https://ncbi.nlm.nih.gov/pubmed/24853766 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.drup.2014.04.001 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|